Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-025503

PRESIDENT AND CEO sold 924 shares at $30.00 ($27,723)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Kintz Samuel · PRESIDENT AND CEO

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2024-10-18 Sale : show line 1 in the form 10b5-1 −924 $30.00 $27,723 1,002,892 I
Open-market sales · 924 sh · avg $30.00 · $27,723
Loading xslF345X05/form4-10222024_081007.xml…